2L+ clear cell renal cell carcinoma (ccRCC)
RCUSArcus BiosciencesCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Casdatifan + Cabozantinib in 2L+ clear cell renal cell carcinoma (ccRCC). The expected timing is based on the latest available company guidance and may change.
ARC-20 trial. 2/15/25- New data at ASCO-GU'25. 2/25/25- Initiate expansion cohorts in Q1 2025. 6/1/25- Presented first combination data at ASCO '25. 10/28/25:- ARC-20 casdatifan+cabo cohort to deliver more mature Phase 1 data in Mid-2026. 02/25/26:- ARC-20 casdatifan+cabo: about 45 patients with ≥12-month follow-up; more mature ORR and PFS data expected in 2026. 05/05/26:- ARC-20 casdatifan+cabozantinib cohort: ~45 IO-experienced ccRCC patients; mature ORR and initial PFS data planned in 2026. 08/05/26:- ARC-20 cabo ORR and initial PFS data expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.